Status:
COMPLETED
Eletriptan Pharmacokinetics In Korean Males
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.
Eligibility Criteria
Inclusion
- healthy male subjects, 18-55 years old
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2
- provide informed consent
Exclusion
- blood pressure \>140/90 mm Hg
- any condition possibly affecting drug absorption
- positive urine drug screen
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01139515
Start Date
July 1 2010
End Date
July 1 2010
Last Update
January 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Seoul, South Korea, 110-744